Diagnostic and prognostic utilities of multimarkers approach using procalcitonin, B-type natriuretic peptide, and neutrophil gelatinase-associated lipocalin in critically ill patients with suspected sepsis by Mina Hur et al.
RESEARCH ARTICLE Open Access
Diagnostic and prognostic utilities of multimarkers
approach using procalcitonin, B-type natriuretic
peptide, and neutrophil gelatinase-associated
lipocalin in critically ill patients with suspected
sepsis
Mina Hur1, Hanah Kim1, Seungho Lee2, Flavia Cristofano3, Laura Magrini3, Rossella Marino3, Chiara Serena Gori3,
Cristina Bongiovanni3, Benedetta Zancla3, Patrizia Cardelli4 and Salvatore Di Somma3*
Abstract
Background: We investigated the diagnostic and prognostic utilities of procalcitonin (PCT), B-type natriuretic peptide
(BNP), and neutrophil gelatinase-associated lipocalin (NGAL) in critically ill patients with suspected sepsis, for whom
sepsis was diagnosed clinically or based on PCT concentrations.
Methods: PCT, BNP, and NGAL concentrations were measured in 340 patients and were followed up in 109 patients.
All studied biomarkers were analyzed according to the diagnosis, severity, and clinical outcomes of sepsis.
Results: Clinical sepsis and PCT-based sepsis showed poor agreement (kappa = 0.2475). BNP and NGAL showed
significant differences between the two groups of PCT-based sepsis (P = 0.0001 and P < 0.0001), although there was no
difference between the two groups of clinical sepsis. BNP and NGAL were significantly different according to the PCT
staging and sepsis-related organ failure assessment subscores (P < 0.0001, all). BNP and PCT concentrations were
significantly higher in the non-survivors than in the survivors (P = 0.0002) and showed an equal ability to predict
in-hospital mortality (P = 0.0001). In the survivors, the follow-up NGAL and PCT concentrations were significantly lower
than the initial values (148.7 ng/mL vs. 214.5 ng/mL, P < 0.0001; 0.61 ng/mL vs. 5.56 ng/mL, P = 0.0012).
Conclusions: PCT-based sepsis diagnosis seems to be more reliable and discriminating than clinical sepsis diagnosis.
Multimarker approach using PCT, BNP, and NGAL would be useful for the diagnosis, staging, and prognosis prediction
in the critically ill patients with suspected sepsis.
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Background
Sepsis is a systemic inflammatory response caused by in-
fection. Progression to severe sepsis and septic shock is
one of the main causes of high morbidity and mortality
in critically ill patients in emergency or intensive care
settings [1,2]. Since prompt and specific treatment in the
patients with severe sepsis and septic shock has shown
improved outcomes, it is crucial to ensure a timely diag-
nosis of this disease progression [3,4]. The sepsis-related
organ failure assessment (SOFA) score has been used to
describe and evaluate organ dysfunctions and failures in
these patients [5].
Procalcitonin (PCT) has been extensively studied in
various clinical settings, and growing evidences support
its potential ability to diagnose sepsis, estimate its sever-
ity, and provide a prognosis [6-8]. Regarding organ dys-
functions and failures, various novel biomarkers have
shown promise in clinical practice. B-type natriuretic
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peptide (BNP) has been used to successfully aid in the
diagnosis of heart failure, and its concentrations corre-
lated with both disease severity and prognosis [9-11].
Neutrophil gelatinase-associated lipocalin (NGAL) has
been regarded as a sensitive, specific, and early predict-
ive biomarker for acute kidney injury (AKI) [12-14]. In a
recent meta-analysis, one of the major findings was that
41% of patients diagnosed with AKI would have been
missed by creatinine alone [13].
A few recent studies reported a combined use of these
novel biomarkers [15,16]. In a multicenter prospective
study (GALLANT trial), the combination of plasma NGAL
and BNP demonstrated clinical implications for risk strati-
fication in the patients with acute heart failure, and plasma
NGAL at discharge was a strong indicator of adverse out-
comes [15]. Our previous study showed the diagnostic util-
ity of plasma NGAL for AKI in the critically ill patients
with suspected sepsis, for whom PCT was used for the
diagnosis and staging of sepsis [16]. If several biomarkers, a
marker for sepsis and respective markers for each organ
dysfunction, are combined together, it will provide more
objective and reliable guide for the diagnosis, risk stratifica-
tion, prognosis, and treatment of sepsis. In the present
study, we wanted to explore the diagnostic and prognostic
utilities of PCT, BNP, and NGAL in critically ill patients
with suspected sepsis, for whom sepsis was diagnosed clin-
ically or based on PCT concentrations.
Methods
Study population
A prospective, observational study was conducted in
two university hospitals: a 400-bed hospital (Sant’ Andrea
Hospital, SAH) in Rome, Italy and a 900-bed hospital
(Konkuk University Hospital, KUH) in Seoul, Korea. Dur-
ing the period from March 2012 to July 2013, a total of
340 patients (109 patients from SAH and 231 patients
from KUH) were enrolled from the emergency depart-
ment (n = 224) or intensive care unit (n = 116). They were
critically ill patients with suspected sepsis, based on clinical
diagnostic criteria of sepsis (e.g. SIRS) [17]. Their medical
records were reviewed for the clinical and laboratory
data. The protocol was designed following the criteria of
the Declaration of Helsinki and was approved by the
ethical committee of each participating hospital. The
study protocol was approved by the Institutional Review
Board (IRB) in each hospital (KUH and SAH). In KUH,
written informed consent from the enrolled patients
was exempted, because the biomarkers were measured
using residual samples that would be discarded, without
additional blood sampling from the patients. In SAH,
written informed consent was obtained from all enrolled
patients for the initial and follow-up data. The patients
were divided into five groups (0 – 4) according to the
cardiovascular, respiratory, and renal subscores of SOFA
score [5]. Their median age was 67.5 years (range, 0 -
102 years), and 177 (52.1%) patients were males. The
median duration of hospital stay was 10 days (range, 1 -
838 days), and in-hospital mortality was observed in 51
(15%) patients. Review of the medical history revealed
cardiac diseases in 179 (52.6%) patients; diabetes in 90
(26.5%) patients; pulmonary diseases in 78 (22.9%) pa-
tients; cancers in 63 (18.5%) patients; gastric diseases in
46 (13.5%) patients; neurologic diseases in 45 (13.2%)
patients; and chronic kidney diseases in 36 (10.6%) patients.
Measurement of BNP, NGAL, and PCT
In the whole population, plasma BNP and NGAL were
measured using the Triage CarioRenal Panel (Alere, Inc.,
San Diego, CA, USA), according to the manufacturer’s
instruction [18]. It is a fluorescence immunoassay for
the quantitative determination of BNP and NGAL in
EDTA-anticoagulated whole blood and plasma specimens.
Briefly, several drops of EDTA-anticoagulated whole blood
are added to the sample port on the device within two
hours after blood collection. Then, the blood cells are
separated from the plasma using a filter contained in the
device. The specimen reacts with fluorescent antibody con-
jugates and flows through the device by capillary action.
Table 1 Distribution of study population according to the procalcitonin concentrations
PCT (ng/mL) Interpretation n Blood culture positive (%) Age (yr) Male (%)
I (<0.05) Healthy 28 1 (3.6) 68 (5 - 89) 13 (46.4)
II (0.05 – 0.49) Local infection 162 10 (6.2) 67 (0 - 100) 90 (55.2)
III (0.5 – 1.99) Systemic infection or sepsis 75 9 (12.0) 65.5 (0 - 96) 31 (41.9)
IV (2.0 – 9.99) Severe sepsis 42 9 (21.4) 70 (0 - 95) 20 (47.6)
V (≥10) Septic shock 33 11 (33.3) 70 (46 - 102) 23 (69.7)
Total 340 40 (11.8) 67.5 (0 - 102) 177 (52.1)
Age is expressed as median value (range).
Blood culture-positive rates tended to increase according to the PCT groups, showing significant differences (I vs. V, P = 0.0097;
II vs. IV, P = 0.0065; II vs. V, P < 0.0001; III vs. V, P = 0.0184).
PCT: procalcitonin.
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Complexes of each fluorescent conjugate are captured on a
discrete zone specific for each analyte. The concentration
of each analyte is directly proportional to the fluorescence
detected in the Triage Meter (Alere, Inc.) and is displayed
approximately 20 mins later. The medical decision points
were regarded as 100 pg/mL and 150 ng/mL for plasma
BNP and NGAL, respectively [13,15].
Serum PCT was measured using the Elecsys BRA
HMS PCT electrochemiluminescence assay (BRAHMS,
Henningsdorf, Germany) in the Roche Cobas e-System
(Roche Diagnostics, Basel, Switzerland) or BRAHMS PCT
sensitive Kryptor immunofluorescent assay system (BRA
HMS). Both are fully automated, sensitive, quantitative
PCT assays with functional sensitivity of 0.06 ng/mL. On
the basis of the previous studies and manufacturers’ recom-
mendation, PCT concentrations were divided into five
groups: < 0.05 ng/mL, group I (healthy); 0.05 – 0.49 ng/mL,
group II (local infection); 0.5 – 1.99 ng/mL, group III (sys-
temic infection or sepsis); 2.0 – 9.99 ng/mL, group IV
(severe sepsis); and ≥ 10 ng/mL, group V (septic shock)
[16,19]. Table 1 shows the distribution of study popula-
tion according to the PCT concentrations.
The samples for BNP, NGAL, and PCT were obtained
simultaneously, when the patients showed acutely ill-
looking appearances with the changes of vital signs and
were suspected of having sepsis [17]. In 109 of all cohort
of 340 patients, NGAL and PCT concentrations were
also followed up after 72 hours of initial measurement.
Statistical analysis
Chi-square test was used to compare the proportions.
Mann-Whitney test was used to compare BNP, NGAL,
and creatinine according to the sepsis diagnosis and to
compare BNP, NGAL, and PCT according to the in-
hospital mortality. Agreement between the diagnosis of
clinical sepsis and PCT-based sepsis was assessed using
Cohen’s Kappa (agreement: < 0.4, poor; 0.4 – 0.75, fair
to good; > 0.75, excellent). Kruskal-Wallis test was used
to compare BNP, NGAL, and creatinine according to the
PCT groups and to compare the distribution of NGAL and
BNP according to the subscores of SOFA score. Paired
t-test was used to compare NGAL and PCT at initial
measurement and follow-up according to the in-hospital
mortality. Receiver operating characteristic (ROC) curves
were analyzed to compare BNP, NGAL, and PCT in pre-
dicting in-hospital mortality and in diagnosing sepsis.
Logistic regression was also used to compare NGAL and
PCT in predicting in-hospital mortality. For the statistical
analyses, SPSS software (version 17.0, SPSS Inc., Chicago,
IL, USA) and MedCalc software (version 12.1.4, MedCalc
Software, Mariakerke, Belgium) were used. P values equal
to or less than 0.05 were considered statistically significant.
Results
According to the PCT concentrations, 44.1% (150/340)
of the patients belonged to the groups of sepsis, severe
sepsis, or septic shock (Table 1). Blood culture-positive
rates increased significantly according to the PCT groups.
When sepsis was diagnosed clinically or based on the
PCT concentrations, the overall concordance rate between
the two diagnoses was 63.8% (217/340), showing a poor
agreement (kappa = 0.2425) (Table 2). In spite of this poor
agreement, the positive rate of blood culture in the pa-
tients with clinical sepsis (21.0%, 25/119) was not different
from that in the patients with PCT-based sepsis (19.3%,
29/150), showing a difference of 1.70 (95% confidence
interval [CI], -8.32% to 12.03%, P = 0.8473).
The concentrations of BNP, NGAL, and creatinine were
compared according to the sepsis diagnosis (Table 3). Al-
though, according to the clinical diagnosis of sepsis, there
was no statistical difference in both BNP and NGAL
Table 2 Comparison between clinical sepsis and
procalcitonin-based sepsis






Negative (n = 221) 144 77
Positive (n = 119) 46 73
0.2425 (0.1398 – 0.3453)
P = 0.0071 (McNemar test).
The critically ill patients with suspected sepsis were diagnosed on the basis of
clinical diagnostic criteria of sepsis (e.g. SIRS) [17].
PCT: procalcitonin; CI: confidence interval.
Table 3 Comparison of NGAL, creatinine, and BNP according to the sepsis diagnosis
Clinical sepsis (n = 119) PCT-based sepsis (n = 150)
Non-sepsis (n = 221) Sepsis (n = 119) Non-sepsis (n = 190) Sepsis (n = 150)
BNP (pg/mL) 72.3 (52.8 – 115.7) 140 (65.5 – 189.3) 66.7 (30.8 – 96.0) 146.5 (93.5 – 223.4)*
NGAL (ng/mL) 184 (161.9 – 233.6) 210 (137.0 – 265.0) 137 (115.0 – 167.0) 333 (255.6 – 448.0)†
Creatinine (mg/dL) 0.94 (0.85 – 1.09) 0.84 (0.71 – 1.10) 0.81 (0.76 – 0.93) 1.12 (0.98 – 1.50)†
*P = 0.0001 vs. non-sepsis.
†P < 0.0001 vs. non-sepsis.
Data are expressed as median (95% confidence interval).
BNP: B-type natriuretic peptide; NGAL: neutrophil gelatinase-associated lipocalin; PCT: procalcitonin.
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concentrations, these two biomarkers significantly dif-
fered between the two groups of PCT-based sepsis. Such
a difference was also observed in the comparison of
creatinine. For the clinical diagnosis of sepsis, the area
under the ROC curve (AUC with 95% CI) for PCT
(0.673 [0.621 – 0.723]) differed significantly from those
of BNP (0.526 [0.472 – 0.580], P < 0.001) and NGAL (0.509
[0.455 – 0.564], P = 0.005). For the PCT-based diagnosis of
sepsis, both BNP and NGAL showed an ability to distin-
guish between the two groups of sepsis. The AUCs (95%
CI) for BNP and NGAL were 0.634 (0.580 – 0.685) and
0.594 (0.539 – 0.646), respectively, showing no statistical
difference between the two AUCs (P = 0.426).
BNP, NGAL, and creatinine all showed significant differ-
ences according to the PCT groups (P < 0.0001 for NGAL
and creatinine; P = 0.0001 for BNP) (Figure 1). The me-
dian concentrations of BNP and NGAL were above the
medical decision points (100 pg/mL and 150 ng/mL, re-
spectively) in septic patients, while that of creatinine was
above the medical decision point (1.2 mg/dL) only in se-
vere sepsis & septic shock patients. The distributions of
BNP and NGAL according to the subscores of SOFA
score are presented in Figure 2. Plasma BNP concentra-
tion was significantly associated with the cardiovascular
and renal subscores of SOFA score (P < 0.0001). Although
plasma BNP concentration differed significantly according
to the respiratory subscore of SOFA score, there was no
increasing tendency. Plasma NGAL concentration was sig-
nificantly associated with the renal subscore of SOFA
score (P < 0.0001).
BNP, NGAL, and PCT concentrations were analyzed
according to the in-hospital mortality (Table 4). In a
total of 340 patients, BNP and PCT concentrations were
significantly higher in the non-survivors than in the sur-
vivors (P = 0.0002, both). There was no statistical differ-
ence in NGAL concentrations between the two groups
(P = 0.1804). Regardless of clinical sepsis or PCT-based
sepsis, BNP concentrations were significantly higher in
the non-survivors than in the survivors (P = 0.0014 and
P = 0.0054). In the ROC curve analysis, both BNP &
PCT showed an equal ability to predict in-hospital mor-
tality: the AUC for BNP and PTC was 0.661 (95% CI,
0.608 – 0.711; P = 0.0001).
The initial and follow-up concentrations of NGAL and
PCT were further compared according to the in-hospital
mortality (Table 5). In the survivors, the follow-up NGAL
and PCT concentrations were significantly lower than
their initial concentrations (P < 0.0001 and P = 0.0012, re-
spectively). In logistic regression, they contributed signifi-
cantly to the prediction of in-hospital mortality. Odds
ratios (95% CI) were 1.0032 (1.0012 – 1.0052) and 1.8485
(1.2742 – 2.6815) in NGAL and PCT, respectively.
Discussion
The potential clinical usefulness of some innovative bio-
markers has been discussed in the diagnosis, staging,
and monitoring of sepsis, and these biomarker-guided
strategies may allow more refined risk stratification and
lead to improved patient care and outcomes [20,21]. To
the best of our knowledge, however, there have been no
studies that investigated the three biomarkers of BNP,
NGAL, and PCT together in the septic patients so far.
In the present study, we investigated the diagnostic
and prognostic utilities of BNP, NGAL, and PCT in crit-
ically ill patients with suspected sepsis. In particular, we
diagnosed and graded the sepsis based on the PCT con-
centrations, in addition to the clinical diagnosis. Notice-
ably, there was a poor agreement between the clinical
diagnosis and PCT-based diagnosis of sepsis (Table 2).
In spite of this poor agreement, the positive rate of
blood culture in the patients with clinical sepsis did not
differ from that in the patients with PCT-based sepsis
(21.0% vs. 19.3%), and the blood culture-positive rates in-
creased significantly according to the PCTgroups (Table 1).
Eleven out of 40 patients with positive blood culture
belonged to PCT groups I or II. Despite being considered
the gold standard for diagnosis, blood cultures are subject
to contamination by skin flora if blood cultures are not
collected using an appropriate aseptic technique [22]. In
this regard, it is possible that the positive blood culture re-
sults might have been due to contamination. In recent
studies, initial PCT concentrations in the emergency de-
partment accurately predicted blood culture positivity in
patients with community-acquired pneumonia [23], and
PCT showed excellent correlation with bacterial load and
(See figure on previous page.)
Figure 1 Comparison of BNP, NGAL, and creatinine according to the PCT groups. (A) The BNP concentrations according to the PCT groups
were: 109 (5 – 1,220) pg/mL; 42.2 (5 – 2,790) pg/mL; 103.5 (5 – 5,000) pg/mL; 129 (5 – 5,000) pg/mL; and 241 (5 – 1,850) pg/mL, respectively
(P = 0.0001). The median values of BNP were all above the medical decision point (100 pg/mL) in septic patients. (B) The NGAL concentrations
according to the PCT groups were: 90.5 (16 – 444) ng/mL; 156 (19 – 1,300) ng/mL; 232 (33 – 1,301) ng/mL; 499.5 (55 – 1,301) ng/mL; and 609
(72 – 1,300) ng/mL, respectively (P < 0.0001). The median values of NGAL were all above the medical decision point (150 ng/mL) in septic
patients. (C) The creatinine concentrations according to the PCT groups were: 0.8 (0.39 – 11.98) mg/dL; 0.82 (0.2 – 9.52) mg/dL; 0.875 (0.2 – 6.9)
mg/dL; 1.49 (0.33 – 6.52) mg/dL; and 1.85 (0.4 – 10.61) mg/dL, respectively (P < 0.0001). The median value of creatinine was above the medical
decision point (1.2 mg/dL) only in severe sepsis & septic shock patients.
Hur et al. BMC Infectious Diseases 2014, 14:224 Page 5 of 8
http://www.biomedcentral.com/1471-2334/14/224
Table 4 Comparison of BNP, NGAL, and PCT according to the in-hospital mortality













BNP (pg/mL) 69 (46.7 – 101.0) 200* (159.1 – 280.2) 48.2 (13.4 – 143.1) 237.0† (165.2 – 356.7) 112.0 (63.8 – 157.5) 253.0‡ (181.2 – 519.2)
NGAL (ng/mL) 184 (159.1 – 222.7) 227 (161.4 – 444.9) 189 (108.6 – 304.7) 218 (143.5 – 375.1) 346 (281.9 – 490.6) 254 (145.5 – 519.5)
PCT (ng/mL) 0.27 (0.23 – 0.39) 0.93* (0.54 – 1.35) 0.76 (0.43 – 1.52) 0.93 (0.63 – 1.34) NA
*P = 0.0002 vs. survivors.
†P = 0.0014 vs. survivors.
‡P = 0.0054 vs. survivors.
Data are expressed as median (95% confidence interval).
BNP: B-type natriuretic peptide; NGAL: neutrophil gelatinase-associated lipocalin; PCT: procalcitonin; NA: not applicable.
Figure 2 Comparison of BNP and NGAL according to the subscores of SOFA score. (A) The BNP concentrations according to the cardiovascular
subscore of SOFA score were: 245.5 (5 – 2,140) pg/mL; 43 (1 – 5,000) pg/mL; 223.9 (12.6 – 1,260) pg/mL; 245 (13.5 – 1,850) pg/mL; and 257 (10.1 – 609)
pg/mL, respectively. The BNP concentration was significantly associated with the cardiovascular subscore of SOFA score (P < 0.0001). (B) The BNP
concentrations according to the respiratory subscore of SOFA score were: 180 (35 – 1,240) pg/mL; 232.5 (5 – 1,370) pg/mL; 281 (5 – 2,140) pg/mL; 43
(5 – 3,070) pg/mL; and 46.6 (5 – 5,000) pg/mL, respectively. Although the BNP concentration was significantly different according to the respiratory
subscore of SOFA score, there was no increasing tendency (P < 0.0001). (C) The BNP concentrations according to the renal subscore of SOFA score
were: 43.7 (5 – 3,070) pg/mL; 147 (5 – 5,000) pg/mL; 266.5 (5 – 4,900) pg/mL; 211.5 (5 – 5,000) pg/mL; and 1,220 (19.4 – 3,170) pg/mL, respectively. The
BNP concentration was significantly associated with the renal subscore of SOFA score (P < 0.0001). (D) The NGAL concentrations according to the
renal subscore of SOFA score were: 137 (16 – 1,301) ng/mL; 234 (33 – 1,300) ng/mL; 612 (59 – 1,301) ng/mL; 1015.5 (127 – 1,300) ng/mL; and 1,300
(444 – 1,300) ng/mL, respectively. The NGAL concentration was significantly associated with the renal subscore of SOFA score (P< 0.0001). Abbreviations:
BNP, B-type natriuretic peptide; NGAL, neutrophil gelatinase-associated lipocalin; SOFA, sepsis-related organ failure assessment.
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could discriminate between blood culture contaminants
and organisms representing bacteremia [24].
Similar to our data, a multicenter study reported a large
disconnect between the perceived severity of heart failure
(as assessed by initial disposition and New York Heart
Association functional class) and the BNP level, empha-
sizing the biomarker-guided therapeutic and monitoring
strategies involving BNP in the patients with heart fail-
ure [9]. Another interesting finding is that the BNP and
NGAL concentrations demonstrated significant differ-
ences according to the presence or absence of sepsis only
when they were compared according to the PCT-based
sepsis (Table 3). Based on these results, PCT-based sepsis
diagnosis seems to be more reliable and discriminating
than clinical sepsis diagnosis.
The assessment of risk stratification and prognosis in
sepsis is based on the clinical scoring systems. However,
they are in general inefficient to provide definite clues
on organ dysfunctions or failures [5,20]. In this study,
BNP, NGAL, and creatinine all showed significant differ-
ences according to the PCT groups (Figure 1). Although
creatinine was increased only in the patients with severe
sepsis & septic shock, BNP and NGAL were increased
above their medical decision points in all septic patients.
Compared with creatinine, NGAL seems to be an early,
objective marker of AKI in relation to sepsis [16]. More-
over, the BNP concentration was significantly associated
with the cardiovascular and renal subscores of SOFA score,
and the NGAL concentration was significantly associated
with the renal subscore of SOFA score (Figure 2). Taken
together, these findings imply the clinical usefulness of
these innovative biomarkers to assess the organ dysfunc-
tions or failures along with the sepsis severity.
We also observed the significant differences of these
biomarkers according to the in-hospital mortality (Table 4).
The initial BNP and PCT concentrations were significantly
higher in the non-survivors than in the survivors, and
both BNP & PCT showed an equal ability to predict in-
hospital mortality. In the survivors, the follow-up NGAL
and PCT concentrations were significantly lower than their
initial concentrations (Table 5). The present findings sup-
port the previous studies, which showed the usefulness of
these biomarkers for prognostic stratification in various
critical care settings [15,25,26]. PCT seems to be associated
with the diagnosis and severity of sepsis, BNP with re-
sponse to circulatory and cardiovascular complications,
and NGAL with AKI in severe sepsis/septic shock. Com-
pared with PCT and BNP, NGAL did not seem to correlate
with mortality. This study is partly limited in that the
follow-up data of biomarkers were available only in one
thirds of the enrolled patients and included only NGAL
and PCT. Accordingly, it is difficult to draw any conclu-
sions from these results, and serial measurement of these
biomarkers would be valuable to estimate the adverse out-
comes in the patients with sepsis.
Conclusions
In conclusion, this is the first study that investigated the
combined use of BNP, NGAL, and PCT in critically ill pa-
tients with suspected sepsis. A substantial discrepancy may
exist between the clinical diagnosis and PCT-based diagno-
sis of sepsis, and PCT-based sepsis diagnosis seems to be
more reliable and discriminating than the clinical diagno-
sis. Multimarker strategy including BNP, NGAL, and PCT
seems to be an objective and useful approach for the diag-
nosis, staging, and prognosis prediction in the critically ill
patients with suspected sepsis. Further studies are war-
ranted to facilitate and refine the combined use of bio-
markers in a variety of critical care settings.
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Table 5 Comparison of NGAL and PCT at initial and follow-up measurements according to the in-hospital mortality









NGAL (ng/mL) 214.5 ± 249.1 148.7 ± 173.3* 727.4 ± 554.5 775.7 ± 562.1
PCT (ng/mL) 5.56 ± 15.4 0.61 ± 2.18† 31.8 ± 72.6 18.4 ± 37.4
*P < 0.0001 vs. initial measurement.
†P = 0.0012 vs. initial measurement.
Both initial and follow-up data were available in 109 patients (96 survivors and 13 non-survivors).
NGAL: neutrophil gelatinase-associated lipocalin; PCT: procalcitonin; SD: standard deviation.
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